IN T RO D U C T I O N
|
|
- Willa Andrews
- 6 years ago
- Views:
Transcription
1 AN OVERVIEW OF RHEUMATOID ARTHRITIS Michele Boutaugh, BSN, MPH* ABSTRACT Rheumatoid arthritis is a systemic autoimmune disease characterized by chronic inflammation that damages synovial joints, especially the joints of the hands and feet. Most patients also experience extra-articular manifestations that can affect a variety of different organs. The disease is particularly common in women and usually has its onset in middle age, during the years when patients have significant responsibilities to their families and employers. More than 2 million Americans are affected by rheumatoid arthritis, with a high risk of disability and premature mortality. Joint damage typically begins during the first 2 years of the disease, but early treatment can help patients preserve function. It is important for primary healthcare professionals to be able to recognize rheumatoid arthritis so that patients can be referred to a rheumatologist within the first 3 months after symptom onset. The presentation and course are highly variable. The onset can be sudden, gradual, or insidious. Common features are symmetrical joint swelling and tenderness or pain on passive motion. Other common signs and symptoms are prolonged morning stiffness, rheumatoid nodules, decreased range of motion, difficulty making a fist, decreased grip strength, deformities in the hands or feet, prolonged morning stiffness, and constitutional symptoms such as fatigue, weakness, fever, loss of appetite, and general malaise. These signs and symptoms are believed to occur because, in response to an unknown antigen, the body activates an inappropriate immune response. An inflammatory *G roup Vice President of Scientific Affairs, Art h r i t i s Foundation, Atlanta, Georgia. Address correspondence to: Michele Boutaugh, BSN, MPH, Group Vice President of Scientific Affairs, Arthritis Foundation, 1330 W. Peachtree Street NW, Atlanta, GA mboutaug@arthritis.org. cascade is activated that causes thickening of the lining of synovial joints. Eventually, cells activated by the inflammatory cascade begin to destroy bone and connective tissue. Several biologic disease-modifying antirheumatic drugs the newer targeted therapies for rheumatoid arthritis are designed to interfere with specific components of the destructive inflammatory cascade. Nurses who make an effort to understand the pathogenesis of rheumatoid arthritis will be best able to teach patients how the new therapies exert their effects. (Adv Stud Nurs. 2007;5(1):8-14) IN T RO D U C T I O N Rheumatoid arthritis (RA) is an autoimmune disease c h a r a c t e r i zed by chronic inflammation in synovial joints, especially the small joints in the hands and feet. In the United States, RA is not as common as osteoarthritis, the type of arthritis associated with the wear and tear of aging, but it is far from rare. The Arthritis Fo u n d a t i o n estimates that RA affects 2.1 million Americans. 1 RA can occur at any age, including during childhood. Women are diagnosed with RA 2.5 times more often than men, and in women, the onset most commonly occurs between the ages of 40 and A 30-ye a r study at the Ma yo Clinic showed that the incidence of RA rose steadily from age 35 until approximately age 85, when it declined sharply among women and slightly among men. 3 RA causes joint damage in 80% to 85% of patients, typically during the first 2 years of the disease, so there is a high risk of disability. 4,5 RA also increases the risk of mortality. According to research conducted before targeted drug therapy was introduced, people with RA are twice as likely to die compared with unaffected people the same age. 6 The leading contributors to the increased risk of death are cardiovascular disease, which accounts for approxi- 8 Vol. 5, No. 1 April 2007
2 mately one third to one half of RA-related deaths, and infection, which is associated with approximately one quarter of such deaths. 7 RA is also known to increase the risk of lymphoma, by a factor of at least 2-fold, and to increase the risk of decreased bone mineral density, even in the absence of corticosteroid therapy. 7 A subset of RA, called older-onset RA, begins after age 60 and is characterized by especially rapid pro g re s- sion of joint damage. Like RA in other adults, olderonset RA is associated with an increased risk of death, especially among patients who are sero p o s i t i ve for rheumatoid factor. 8 This article re v i ews the causes and consequences of joint damage in RA, the clinical manifestations in adults, and how the disease is diagnosed. Special care is taken to explain the autoimmune response invo l ved in RA, so nurses will have a better understanding of the newe r d rugs that target this re s p o n s e. F i g u re 1. Normal Synovial Joint Compared with a Synovial Joint Affected by Rheumatoid Arthritis JOINT DAMAGE RA is the most common type of a group of diseases called inflammatory art h ropathies. (Other examples are psoriatic arthritis and systemic lupus ery t h e m a t o s u s. ) In the case of RA, the chronic inflammation principally affects synovial joints joints where there is space b e t ween 2 articulating bones. In a synovial joint, the bones are cove red with cartilage, enclosed in a fibro u s capsule, and lubricated by synovial fluid. A thin membrane called the s y n ov i u m lines the joint (Fi g u re 1). 9 The joint symptoms of RA are caused by synov i- tis inflammation of the synovium. The synovium is i n vaded by immune system cells and thickens, causing the joint to swell and feel puffy to the touch (Fi g u re 2). As the synovium ove r g rows, a tissue called p a n n u s forms, which acts like a low-grade malignancy, eve n t u- ally destroying bone, cartilage, and connective tissues. 1 0 In addition, the inflammatory response increases blood f l ow to affected joints, sometimes causing them to look reddened and to feel warm to the touch. Reprinted with permission from National Institute of Arthritis and Musculoskeletal and Skin Diseases. Rheumatoid A rt h ri t i s. Bethesda, Md; NIH publication Revised May F i g u re 2. S welling in the Hand from T h i c kening of the Synov i u m CLINICAL PRESENTATION AND DIAGNOSIS Patients with RA va ry widely with re g a rd to the age of onset, number of joints invo l ved, and degree of disease severity and course. Some patients have only mild symptoms and re q u i re only anti-inflammatory medication or minor lifestyle changes. Others have joint d e s t ruction even at the time of presentation. So m e Reprinted with permission from Turkiewicz et al. Clinical Care in the Rheumatic Diseases. 3rd ed. Atlanta, Ga: Association of Rheumatology Health Professionals; Johns Hopkins Advanced Studies in Nursing 9
3 patients experience flares and remissions, whereas others h a ve a pro g re s s i ve course. Howe ve r, most patients with RA have prolonged morning stiffness ( 1 hour) and symmetrical joint invo l vement (joints on both sides of the body are affected, such as the left and right wrists). 1 1 Because the clinical presentation of RA is so va r i a b l e, diagnosis in the early stages can be difficult. No single diagnostic test or finding conclusively confirms the p resence of RA, and symptoms may wax and wane. 1 1 In 1957, the American Rheumatism Association, now k n own as the American College of Rheumatology, published classification criteria for RA for use in clinical trials. The Table lists the criteria as revised in T h e criteria are a useful reminder of common manifestations of RA, although there are limitations in their application in clinical practice as a diagnostic tool. 1 3 As show n in a large, longitudinal study, RA can present first as u n d i f f e rentiated arthritis that does not meet the classification criteria of RA or any other specific clinical disease c a t e g o ry. 1 4 In some cases, a person will meet the criteria on one visit but not another, or can eventually be diagnosed as having another disease. 1 5 Early recognition is vital, however. Disease-modifying treatment has the best chance of reducing joint damage if it is started early, within 3 months after diagnosis. Therefore, a useful goal is to have patients consult a rheumatologist within 3 months after symptom onset. 16 The diagnosis of RA is generally based on 4 categories of identifying characteristics: symptoms, physical signs, laboratory test results, and radiographic (X-ray) findings. Assessment often needs to be repeated at least once before the diagnosis can be established. IDENTIFYING CHARACTERISTICS SYMPTOMS RA can affect any joint, but the most characteristic early symptoms are pain or tenderness on passive motion and stiffness in the metacarpophalangeal (MCP) joints and proximal interphalangeal (PIP) joints of both hands (Figure 3). Other joints commonly affected are the wrists, elbows, ankles, metatarsophalangeal (MTP) joints in the feet, the temporomandibular joint, knees, hips, and cervical spine. Constitutional symptoms are also common because RA is a systemic disease. These can include fatigue, weakness, fever, a general feeling of ill health, and loss of appetite with weight loss. 17 Table.The 1987 Revised Criteria for the Classification of Rheumatoid Arthritis* Criterion Definition 1. Morning stiffness Morning stiffness in and around the joints, lasting at least 1 hour before maximal improvement 2. Arthritis of 3 or more joints 3. Arthritis of hand joints At least 3 joint areas simultaneously have had soft tissue swelling or fluid (not bony overgrowth alone) observed by a physician. The 14 possible areas are right or left PIP, MCP, wrist, elbow, knee, ankle, and MTP joints. At least 1 area swollen (as defined above) in a wrist, MCP, or PIP joint 4. Symmetric arthritis Simultaneous involvement of the same joint areas (as defined in 2) on both sides of the body (bilateral involvement of PIPs, MCPs, or MTPs is acceptable without absolute symmetry) 5. Rheumatoid nodules Subcutaneous nodules, over bony prominences, or extensor surfaces, or in juxta-articular regions, observed by a physician 6. Serum rheumatoid factor 7. Radiographic changes Demonstration of abnormal amounts of serum rheumatoid factor by any method for which the result has been positive in <5% of normal control subjects Radiographic changes typical of rheumatoid arthritis on posteroanterior hand and wrist radiographs, which must include erosions or unequivocal bony decalcification localized in or most marked adjacent to the involved joints (osteoarthritis changes alone do not qualify) *For classification purposes, a patient shall be said to have rheumatoid arthritis if he has satisfied at least 4 of these 7 criteria. Criteria 1 through 4 must have been present for at least 6 weeks. Patients with 2 clinical diagnoses are not excluded. Designation as classic, definite, or probable rheumatoid arthritis is not to be made. MCP = metacarpophalangeal; MTP = metatarsophalangeal; PIP = proximal interphalangeal. Reprinted with permission from Arnett et al. A rt h ritis Rheum. 1988;31: Vol. 5, No. 1 April 2007
4 PHYSICAL SIGNS Inflamed joints can be swollen and, on careful examination, may feel warm to the touch. Decreased range of motion in the joints, difficulty making a fist, and decreased grip strength are other important clues. Over time, some patients with RA develop deformities in the hands or feet. 15,18 LABORATORY TEST RESULTS Patients with RA frequently have normal laboratory test results, especially in early disease. Therefore, although laboratory abnormalities can support a diagnosis of RA, by themselves, they are not diagnostic. For example, rheumatoid factor (RF), an abnormal immunoglobulin antibody, is present in 70% to 80% of patients with RA, but it is also present in some healthy people and in people with certain other diseases. A negative test for RF does not mean that RA is not present, and an abnormal test does not mean that RA is present. 15 Antibodies to cyclic citrullinated peptide (anti- CCP antibodies) are a more specific marker for RA. The sensitivity of testing for these antibodies (ability to rule out RA that is not present) appears to be 90% to 98%, and the specificity (ability to find RA that is present) is no worse than that of RF, 50% to 80%. 19,20 Some other laboratory abnormalities often found in patients with RA include mild anemia, thrombocytosis, and an elevated erythrocyte sedimentation rate or elevated level of C-reactive protein (markers of inflammation). 15 RADIOGRAPHIC FINDINGS In many patients, RA develops first in the MCP, PIP, or MTP joints, so usually the first radiographs taken are of the hands and feet. The earliest radiographic signs of RA are symmetrical loss of cartilage, which results in joint space narrowing. Loss of cartilage and erosions (holes in the bone) first appear at the corners of the joints, where the cartilage is thinnest. As with laboratory tests, a normal radiograph does not necessarily mean that RA is not present. 11 EXTRA-ARTICULAR MANIFESTATIONS Because RA is a systemic disease, it can cause several extra-articular (outside the joint) manifestations. Men, patients with relatively more severe disease, and patients who test positive for RF are more likely than others to have extra-articular involvement. 15 F i g u re 3. Comparison of the Joints in the Hand A f fected in Osteoarthritis and Rheumatoid A rt h r i t i s DIP = distal interphalangeal; MCP = metacarpophalangeal; PIP = proximal interphalangeal. Reprinted with permission from Bruce et al. Nurse Pract. 2005;30:28-29, 32-27, Rheumatoid nodules (firm, nontender subcutaneous nodules that are not attached to underlying bone or overlying skin) occur in approximately 30% of patients with RA. Such nodules are most commonly found at pressure points such as the elbow, the back of the forearm, and MCP joints. Usually, they are asymptomatic, but they can be painful. They may resolve spontaneously. 17 Some other common extra-articular manifestations of RA are: cardiovascular involvement, including atherosclerotic heart disease, myocarditis, pericarditis, and vasculitis; pleurisy (inflammation of the membrane lining the lungs); Sjögren s syndrome (impaired secretion of saliva and tears, leading to dry mouth and dry eyes); tenosynovitis; and eye disease (scleritis). 15 DIFFERENTIAL DIAGNOSIS Os t e o a rthritis most frequently affects the we i g h t - bearing joints, such as the hip, but it can be confused with RA when it invo l ves the hands. Os t e o a rthritis is m o re likely to affect the distal interphalangeal (DIP) joints and PIP joints than the MCP joints (Fi g u re 3). W h e reas RA-affected joints usually feel soft and s p o n g y, joints affected by osteoarthritis are typically h a rd and bony. Patients with osteoarthritis often have l o c a l i zed, asymmetric join invo l vement and generally experience morning stiffness and constitutional symp- Johns Hopkins Advanced Studies in Nursing 11
5 toms to a much lesser degree than patients with RA do. T h e re are no characteristic laboratory abnormalities. 1 1 Psoriatic arthritis, like RA, is an inflammatory arthropathy. Many patients present with a symmetric arthritis involving the MCP and PIP joints, in some cases many years before the onset of skin disease. Some of the signs that can point toward the correct diagnosis are involvement of DIP joints, psoriatic skin lesions or a family history of psoriasis, and pitting of the nails or changes in their color, texture, and structure. 15 Some of the other conditions that may be considered in the differential diagnosis of RA are fibromyalgia, gout, inflammatory bowel disease, polymyalgia rheumatica, reactive arthritis, Reiter s syndrome, systemic sclerosis, systemic lupus erythematosus, and viral infections that present with joint involvement. 21 ETIOLOGY The etiology of RA is unknown, but it likely invo l ve s multiple factors, including a genetic susceptibility and e n v i ronmental triggers. The major genetic risk factors for RA are certain forms of the HLA-DR gene (human leukocyte antigen gene, subtype DR). 22 Mo re re c e n t l y, it was determined that at least 1 other gene, PTPN22, i n c reases susceptibility to RA. 23 This gene influences the age of onset of RA; people who have it develop the disease 2 years earlier, on average, than those without it. Two other genes, CTLA4 and PADI4, have we a k e r, m o re tentative connections with RA. 23 These findings are i m p o rtant to scientists, but they do not yet affect clinical practice. Genetic factors do help explain the disease va r i- ability and why the incidence and pre valence of RA va ry considerably among countries, with Finland and the United States having the highest rates. 24 For years it has been considered likely that RA has 1 or more environmental causes, in addition to genetic causes. The most well-known environmental risk factor for RA is smoking. 25 An important advance occurred in January 2006, when Swedish researchers reported a new model for the etiology of RA. 25 The scientists found that the risk of RA skyrocketed in people who were cigarette smokers and also had at least 1 copy of the risky HLA-DR genes. However, the smoking-genetics interaction held true only in people with RA who had anti-ccp antibodies, not in those without such antibodies. The Swedish team speculates that an immune response to citrullinated proteins is the first step in the development of RA. It appears that this immune response can be induced by long-term exposure to cigarette smoke, and that it is most likely to occur in people with HLA-DR genes. 25 More research is required to determine exactly how and when the immune system is activated in RA. In the meantime, it is important for nurses to understand how the immune response proceeds because the newer drug therapies for RA target various immune system components. PATHOGENESIS: THE INFLAMMATORY CASCADE RA is an autoimmune disease, meaning that the immune system mounts an attack against healthy tissues. The original antigen the substance that triggers the immune response is unknown; it might be an infectious agent or even a self-protein that the body mistakes as a foreign body. However, much is known about how the disease progresses. The antigen activates, or turns on, immune system cells called T cells, causing them to proliferate and invade 1 or more joints (Figure 4). In turn, T cells activate other immune system cells, such as macrophages, neut rophils, and fibroblasts. These cells secre t e cytokines proteins that can have direct inflammatory effects or stimulate the production of inflammatory substances. Important proinflammatory cytokines in RA are tumor necrosis factor-α (TNF-α), interleukin- F i g u re 4. Depiction of the Inflammatory Cascade that P roduces Joint Damage in Rheumatoid A rt h r i t i s HLA-DR = human leukocyte antigen gene, subtype DR; IFN = interferon; IL = interleukin; RFs = rheumatoid factors; TNF = tumor necrosis factor. Adapted with permission from Arend et al. A rt h ritis Rheum. 1990;33: Vol. 5, No. 1 April 2007
6 1 (IL-1), and IL In addition to activating immune system cells, T cells promote the proliferation of osteoclasts cells that break down bone. 27 Other important players are B cells, which pro d u c e rheumatoid factor antibodies and anti-ccp antibodies ( Fi g u re 4). Anti-CCP antibodies are directly invo l ved in tissue injury. 28 Rheumatoid factors react with immunoglobulin to form immune complexes that activate inflammatory reactions, which eventually can re s u l t in joint damage and the extra-articular manifestations. Among their other effects, B cells can directly infiltrate the joints, produce T N F -αand IL-6, and stimulate f i b roblasts to release destru c t i ve enzymes. 29 B cells eve n help activate T cells in fact, there is evidence that in s y n ovial joints, T-cell activation is dependent on B cells. 30 Cells in the synovium (called synoviocytes) also are i m p o rtant in the RA disease process. The proliferation of s y n oviocytes is what leads to thickening of the synov i u m and pannus formation. Fu rt h e r m o re, synov i o c y t e s, along with cells in cartilage called chondrocytes, re l e a s e collagenase and other proteases (enzymes) that dire c t l y d e s t roy the joint tissues. 31, 32 It is important to understand that the inflammatory cascade is not a chain of events, but rather a web of interrelated reactions that overlap in time. 27 This pro b a b l y explains why combination therapy, in which multiple d rugs are used to suppress different aspects of the immune response, is generally more successful than a single dru g. 33 Biologic disease-modifying antirheumatic dru g s the newer targeted therapies for RA are designed to i n t e rf e re with specific aspects of the inflammatory cascade. Fi ve of them are designed to interf e re with production of cytokines: etanercept, infliximab, and adalimumab target T N F -α; anakinra targets IL-1; and tocilizumab (not yet commercially available) targets IL- 6. The other 2 biologics approved for RA have differe n t mechanisms: rituximab depletes B cells, and abatacept w o rks early in the inflammatory response, targeting T- cell activation. These drugs are discussed in detail elsew h e re in this issue. CONCLUSIONS RA is a chronic, inflammatory autoimmune disease that affects synovial joints and other parts of the body. It is more common in women than in men, and in adults it is more common after age 35. RA is a painful, debilitating disease with unknown etiology and no known cure. However, early diagnosis and treatment can decrease or eliminate joint damage, helping patients maintain function. With an estimated 2 million Americans affected by RA, it is likely that any nurse in a general practice will encounter patients with this disease. Nurses need to know the signs and symptoms of rheumatoid arthritis and be aware of the importance of referral to a rheumatologist within the first 3 months after symptom onset. REFERENCES 1. Arthritis Foundation. Rheumatoid arthritis fact sheet Available at: Newsroom/FactSheets/Rheumatoid_Arthritis_Fact_ Sheet.pdf. Accessed February 5, L a w rence RC, Helmick CG, Arnett FC, et al. Estimates of the p revalence of arthritis and selected musculoskeletal disord e r s in the United States. A rthritis Rheum. 1998;41: Gabriel SE, Crowson CS, O'Fallon WM. The epidemiology of rheumatoid arthritis in Rochester, Minnesota, Arthritis Rheum. 1999;42: Fuchs HA, Kaye JJ, Callahan LF, et al. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol. 1989;16: van der Heijde DM. Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol. 1995;34(suppl 2): Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994;37: Mikuls TR. Co-morbidity in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2003;17: Mikuls TR, Saag KG, Criswell LA, et al. Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa Women's Health Study. Ann Rheum Dis. 2002;61: National Institute of Arthritis and Musculoskeletal and Skin Diseases. Rheumatoid Arthritis. Bethesda, Md; NIH publication Revised May Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell. 1996;85: Bruce ML, Peck B. New rheumatoid arthritis treatments. Nurse Pract. 2005;30:28-29, 32-27, Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31: American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum. 2002;46: Symmons DP, Silman AJ. Aspects of early arthritis. What determines the evolution of early undifferentiated arthritis and rheumatoid arthritis? An update from the Norfolk Arthritis Register. Arthritis Res Ther. 2006;8: Turkiewicz AM, Moreland LW. Rheumatoid arthritis. In: Johns Hopkins Advanced Studies in Nursing 13
7 Bartlett SJ, Bingham CO, Maricic MM, Iversen MD, Ruffing V, eds. Clinical Care in the Rheumatic Diseases. 3rd ed. Atlanta, Ga: Association of Rheumatology Health Professionals; O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med. 2004;350: Turkoski BB. Rheumatoid arthritis and the Arava (leflunomide) controversy. Orthop Nurs. 2003;22: Banning M. The principles of inflammation in the development of rheumatoid arthritis. Br J Nurs. 2005;14: Schellekens GA, Visser H, de Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000;43: Jansen TL, Bruyn GA. Diagnostic value of anticyclic citrullinated peptide antibody in rheumatoid arthritis [letter]. J Rheumatol. 2004;31: Rindfleisch JA, Muller D. Diagnosis and management of rheumatoid arthritis. Am Fam Physician. 2005;72: Jawaheer D, Gregersen PK. Rheumatoid arthritis: the genetic components. Rheum Dis Clin North Am. 2002;28: Plenge RM, Padyukov L, Remmers EF, et al. Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet. 2005;77: Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum. 2006;36: Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006;54: Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344: Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423: Kuhn KA, Kulik L, Tomooka B, et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest. 2006;116: Silverman GJ, Carson DA. Roles of B cells in rheumatoid arthritis. Arthritis Res Ther. 2003;5(suppl 4):S Weyand CM, Seyler TM, Goronzy JJ. B cells in rheumatoid synovitis. Arthritis Res Ther. 2005;7(suppl 3):S Arend WP, Dayer JM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum. 1990;33: Kay J, Calabrese L. The role of interleukin-1 in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 2004;43(suppl 3):iii2-iii Cannella AC, O'Dell JR. Early rheumatoid arthritis: pitfalls in diagnosis and review of recent clinical trials. Drugs. 2006;66: Vol. 5, No. 1 April 2007
Patient #1. Rheumatoid Arthritis. Rheumatoid Arthritis. 45 y/o female Morning stiffness in her joints >1 hour
Patient #1 Rheumatoid Arthritis Essentials For The Family Medicine Physician 45 y/o female Morning stiffness in her joints >1 hour Hands, Wrists, Knees, Ankles, Feet Polyarticular, symmetrical swelling
More informationUnderstanding Rheumatoid Arthritis
Understanding Rheumatoid Arthritis Understanding Rheumatoid Arthritis What Is Rheumatoid Arthritis? 1,2 Rheumatoid arthritis (RA) is a chronic autoimmune disease. It causes joints to swell and can result
More informationImmunological Aspect of Ozone in Rheumatic Diseases
Immunological Aspect of Ozone in Rheumatic Diseases Prof. Dr. med. Z. Fahmy Chief Consulting Rheumatologist Augusta Clinic for Rheumatic Diseases And Rehabilitation Bad Kreuznach Germany Rheumatoid arthritis
More informationRheumatoid Arthritis
Rheumatoid Arthritis Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation of the joints. Autoimmune diseases are illnesses that occur when the body's tissues are mistakenly
More informationRheumatoid Arthritis. Manish Relan, MD FACP RhMSUS Arthritis & Rheumatology Care Center. Jacksonville, FL (904)
Rheumatoid Arthritis Manish Relan, MD FACP RhMSUS Arthritis & Rheumatology Care Center. Jacksonville, FL (904) 503-6999. 1 Disclosures Speaker Bureau: Abbvie 2 Objectives Better understand the pathophysiology
More informationRequirements in the Development of an Autoimmune Disease Amino Acids in the Shared Epitope
+ T cell MHC/self-peptide MHC/Vβ Induction of + T H 1 mediated autoimmunity: A paradigm for the pathogenesis of rheumatoid arthritis, multiple sclerosis and type I diabetes APC Activated autoreactive +
More informationRheumatoid Arthritis. Marge Beckman FALU, FLMI Vice President RGA Underwriting Quarterly Underwriting Meeting March 24, 2011
Rheumatoid Arthritis Marge Beckman FALU, FLMI Vice President RGA Underwriting Quarterly Underwriting Meeting March 24, 2011 The security of experience. The power of innovation. www.rgare.com Case Study
More informationRheumatoid arthritis
Rheumatoid arthritis 1 Definition Rheumatoid arthritis is one of the most common inflammatory disorders affecting the population worldwide. It is a systemic inflammatory disease which affects not only
More informationRheumatoid Arthritis
Rheumatoid Arthritis Introduction Rheumatoid arthritis is a fairly common joint disease that affects up to 2 million Americans. Rheumatoid arthritis is one of the most debilitating forms of arthritis.
More informationEtiology: Pathogenesis Clinical manifestation Investigation Treatment Prognosis
Etiology: Pathogenesis Clinical manifestation Investigation Treatment Prognosis JIA is the most common rheumatic disease in childhood and a major cause of chronic disability. Etiology: Unknown, but may
More informationAmino acid sequences in the β chain HLA- DRB*0401 molecules dictate susceptibility to RA Amino Acids in the Shared Epitope
MHC/self-peptide MHC/Vβ TCR Vβx + Vβx T cell Induction of + TH1 mediated autoimmunity: A paradigm for the pathogenesis of rheumatoid arthritis, multiple sclerosis and APC type I diabetes TCR Vβx Activated
More informationRheumatoid Arthritis
Rheumatoid Arthritis What is rheumatoid arthritis? Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation of the joints. Rheumatoid arthritis can also cause inflammation of
More informationWhen is it Rheumatoid Arthritis When to Refer
When is it Rheumatoid Arthritis When to Refer Nancy A. Brown, DO Spring 2015 When is it Rheumatoid Arthritis When to Refer Learning objectives To review the definition and epidemiology of Rheumatoid Arthritis
More informationTypes of osteoarthritis
ARTHRITIS Osteoarthritis is a degenerative joint disease is the most common joint disorder. It is a frequent part of aging and is an important cause of physical disability in persons older than 65 years
More informationRheumatoid Arthritis. Improving Outcomes in RA: Three Pillars. RA: Chronic Joint Destruction and Disability What We Try to Prevent
Rheumatoid Arthritis Modern Management of Common Problems in Rheumatology: Rheumatoid Arthritis Jonathan Graf, M.D. Associate Professor of Medicine, UCSF Division of Rheumatology, SFGH Director, UCSF Rheumatoid
More informationCase reports CASE 1. A 67-year-old white man had back pain since the age. our clinic several years later with progressive symptoms.
Annals of the Rheumatic Diseases, 1982, 41, 574-578 Late-onset peripheral joint disease in ankylosing spondylitis MARC D. COHEN AND WILLIAM W. GINSBURG From the Division ofrheumatology and Internal Medicine,
More informationAOS 3: Rheumatoid Arthritis
AOS 3: Rheumatoid Arthritis Arthritis (General) = inflamed joint - NOT a single disease: covers >100 types - Involves disability + decreased quality of life o Can also occur in young people (not just the
More informationSubject: Remicade (Page 1 of 5)
Subject: Remicade (Page 1 of 5) Objective: I. To ensure that Health Share/Tuality Health Alliance (THA) has a process by which the appropriate utilization of Remicade (Infliximab) for members whose diagnosis
More informationObjectives. Joint Pain. Case 1. Rheumatology for the Primary MD (Not just your grandmother s disease) 12/4/2010
Objectives Rheumatology for the Primary MD (Not just your grandmother s disease) Identify when it is appropriate to refer for rheumatologic evaluation Autoimmune/ Inflammatory v. noninflammatory disease
More informationPain or stiffness in joints after periods of inactivity or excessive use
Arthritis Awareness* Some older adults call it Arthur ; others refer to it as their constant compassion, but most describe it as extremely painful Arthritis is a chronic joint disease It is commonly believed
More informationAUTOIMMUNITY CLINICAL CORRELATES
AUTOIMMUNITY CLINICAL CORRELATES Pamela E. Prete, MD, FACP, FACR Section Chief, Rheumatology VA Healthcare System, Long Beach, CA Professor of Medicine, Emeritus University of California, Irvine Colonel
More informationAUTOIMMUNITY TOLERANCE TO SELF
AUTOIMMUNITY CLINICAL CORRELATES Pamela E. Prete, MD, FACP, FACR Section Chief, Rheumatology VA Healthcare System, Long Beach, CA Professor of Medicine, Emeritus University of California, Irvine Colonel
More informationUnderstanding Rheumatoid Arthritis
Understanding Rheumatoid Arthritis Contents Introduction...3 What is rheumatoid arthritis?...4 Symptoms of rheumatoid arthritis... 5 What causes rheumatoid arthritis?... 10 The role of genes and family
More informationRheumatoid Arthritis. Rheumatoid Arthritis. RCS 6080 Medical and Psychosocial Aspects of Rehabilitation Counseling. Rheumatic Diseases
RCS 6080 Medical and Psychosocial Aspects of Rehabilitation Counseling Rheumatic Diseases The prevalence of rheumatoid arthritis in most Caucasian populations approaches 1% among adults 18 and over and
More informationA 3-page standard protocol to evaluate rheumatoid arthritis (SPERA): Efficient capture of essential data for clinical trials and observational studies
A 3-page standard protocol to evaluate rheumatoid arthritis (SPERA): Efficient capture of essential data for clinical trials and observational studies T. Pincus Division of Rheumatology and Immunology,
More informationUltrasound in Rheumatology
Arthritis Research UK Primary Care Centre Winner of a Queen s Anniversary Prize For Higher and Further Education 2009 Ultrasound in Rheumatology Alison Hall Consultant MSK Sonographer/Research Fellow Primary
More informationMr. OA: Case Presentation
CLINICAL CASES Case 1: Mr. OA OA Mr. OA: Case Presentation 62-year-old lawyer Mild left knee pain for 3 month, but became worse 1 week ago No swelling 1 week earlier: 2-hour walk in the countryside 2 days
More informationMary Derlacki, FNP. No financial relationships to disclose. Office Rheumatology for the Nurse Practitioner. Rheumatoid Arthritis
Office Rheumatology for the Nurse Practitioner Mary Derlacki, FNP Drs. Cassell and Boren Eugene, OR 541-687-0816 mderlacki@comcast.net No financial relationships to disclose Rheumatoid Arthritis 1% of
More informationJuvenileIdiopathicArthritis. Dr Johan Siebert
JuvenileIdiopathicArthritis Dr Johan Siebert 1 NORMAL DIARTHRODIAL JOINT Synovial is a thin membrane enclosing the joint space The joint space contains fluid that bathes the joint and reduces friction
More informationI nuovi criteri ACR/EULAR per la classificazione dell artrite reumatoide
I nuovi criteri ACR/EULAR per la classificazione dell artrite reumatoide Pierluigi Macchioni Struttura Complessa di Reumatologia, Ospedale di Reggio Emilia Topics 1987 ACR classification criteria for RA
More informationMAF Shalaby Prof. Rheumatology Al Azhar University, Cairo, Egypt.
MAF Shalaby Prof. Rheumatology Al Azhar University, Cairo, Egypt. AUTOIMMUNE DISEASE RA SLE VASCULITIS RELAPSING POLYCHONDRITIS SS DM/PM SJOGREN S SYNDROME RHEUMATOID ARTHRITIS Classically immune mediated
More informationMMS Pharmacology Lecture 2. Antirheumatic drugs. Dr Sura Al Zoubi
MMS Pharmacology Lecture 2 Antirheumatic drugs Dr Sura Al Zoubi Revision Rheumatoid Arthritis Definition (RA): is the most common systemic inflammatory disease characterized by symmetrical inflammation
More informationRHEUMATOLOGY OVERVIEW. Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center
RHEUMATOLOGY OVERVIEW Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center What is Rheumatology? Medical science devoted to the rheumatic diseases
More informationKelley's Textbook of Rheumatology. 2 Volume Set. Text with Internet Access Code for Premium Consult Edition
Kelley's Textbook of Rheumatology. 2 Volume Set. Text with Internet Access Code for Premium Consult Edition Firestein, G ISBN-13: 9781437717389 Table of Contents VOLUME I STRUCTURE AND FUNCTION OF BONE,
More information1.0 Abstract. Title. Keywords. Rationale and Background
1.0 Abstract Title A Prospective, Multi-Center Study in Rheumatoid Arthritis Patients on Adalimumab to Evaluate its Effect on Synovitis Using Ultrasonography in an Egyptian Population Keywords Synovitis
More informationB cells: a fundamental role in the pathogenesis of rheumatoid arthritis?
Rheumatology 2005;44(Suppl. 2):ii3 ii7 B cells: a fundamental role in the pathogenesis of rheumatoid arthritis? doi:10.1093/rheumatology/keh616 The role of T cells in the pathogenesis of RA is well established,
More informationAches and Pains in Rheumatology: Is it Fibromyalgia, Osteoarthritis, or Rheumatoid Disease?
Aches and Pains in Rheumatology: Is it Fibromyalgia, Osteoarthritis, or Rheumatoid Disease? SCOTT T ANDERSON, MD, PHD, FACR, CCHP-P CLINICAL PROFESSOR Menu(rotating) DIVISION OF RHEUMATOLOGY, ALLERGY,
More informationTreating Rheumatologic Disease in Arizona: Good News, Bad News
Treating Rheumatologic Disease in Arizona: Good News, Bad News Jeffrey R. Lisse, M.D. Ethel P. McChesney Bilby Professor of Medicine Chief, Section of Rheumatology University of Arizona School of Medicine
More informationRemicade (Infliximab)
Remicade (Infliximab) Policy Number: Original Effective Date: MM.04.016 11/18/2003 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 07/26/2013 Section: Prescription Drugs Place(s)
More informationSeronegative Arthritis. Dr Mary Gayed 25 th April 2018
Seronegative Arthritis Dr Mary Gayed 25 th April 2018 Overview Description of the conditions Discussion of symptoms & investigations that may be required Discussion of management and treatment Questions
More informationThe Rheumatoid Hand Deformities & Management. Dr. Anirudh Sharma Resident Department of Orthopedics
+ The Rheumatoid Hand Deformities & Management Dr. Anirudh Sharma Resident Department of Orthopedics + Why is Rheumatoid Arthritis important? + RA is a very debilitating disease median life expectancy
More informationSystemic forms of stiffness
Systemic forms of stiffness ANNA LITWIC CONSULTANT RHEUMATOLOGIST SALISBURY DISTRICT HOSPITAL CLINICAL RESEARCH FELLOW MRC LIFECOURSE EPIDEMIOLOGY UNIT Overview Rheumatoid arthritis Know it when you see
More informationRheumatoid Arthritis. By: Hadi Esmaily (PharmD., BCCP, MBA) Department of Clinical Pharmacy, Shahid Beheshti Medical University
Rheumatoid Arthritis By: Hadi Esmaily (PharmD., BCCP, MBA) Department of Clinical Pharmacy, Shahid Beheshti Medical University Introduction RA is a Chronic, Systemic, Inflammatory disorder of unknown etiology
More informationJeopardy. What s the rash? $100 $100 $100 $100 $100 $200 $200 $200 $200 $200 $300 $300 $300 $300 $300 $400 $400 $400 $400 $400
Jeopardy Antibodies & more antibodies Aching joints What s the rash? Potpourri Image Challenge $100 $100 $100 $100 $100 $200 $200 $200 $200 $200 $300 $300 $300 $300 $300 $400 $400 $400 $400 $400 $500 $500
More informationRheumatology Cases for the Internist
Rheumatology Cases for the Internist Marc C. Hochberg, MD, MPH Professor of Medicine Head, Division of Rheumatology and Clinical Immunology Vice Chair, Department of Medicine University of Maryland School
More informationHistory Taking and the Musculoskeletal Examination
History Taking and the Musculoskeletal Examination Introduction A thorough rheumatologic assessment is performed within the context of a good general evaluation of the patient. The patient should be undressed
More informationRheumatoid Arthritis in Asians
NO DISCLOSURES Rheumatoid rthritis in sians Mary C. Nakamura M.D. Professor of Medicine, UCSF Rheumatoid rthritis Rheumatoid rthritis Polyarthritis of synovial lined joints Inflammatory Characteristic
More informationPsoriatic Arthritis Shared Decision Making
Psoriatic Arthritis Shared Decision Making Disease Modifying Drug Therapy DMARDs Therapy El Miedany et al. Ann Rheum Dis 74(Suppl2): 1002 DOI: 10.1136/annrheumdis-2015-eular.1410 www.rheumatology4u.com
More informationUsing ENBREL to Treat Rheumatoid and Psoriatic Arthritis
Using ENBREL to Treat Rheumatoid and Psoriatic Arthritis Writing White Papers class Bellevue Community College TABLE OF CONTENTS TABLE OF CONTENTS...2 OVERVIEW...3 RHEUMATOID ARTHRITIS... 3 JUVENILE RHEUMATOID
More informationA Patient s Guide to Psoriatic Arthritis
A Patient s Guide to Psoriatic Arthritis Glendale Adventist Medical Center 1509 Wilson Terrace Glendale, CA 91206 Phone: (818) 409-8000 DISCLAIMER: The information in this booklet is compiled from a variety
More informationInflammatory rheumatic diseases
Learning objectives Inflammatory rheumatic diseases Bruce Kidd Barts & The London, Queen Mary, University of London To understand: 1. prevalence and range of the rheumatological s 2. clinical features
More informationFor more information about how to cite these materials visit
Author(s): David A. Fox, M.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution Non-Commercial 3.0 License: http://creativecommons.org/licenses/by-nc/3.0/
More informationPATHOGENESIS OF RHEUMATOID ARTHRITIS
PATHOGENESIS OF RHEUMATOID ARTHRITIS Division of Rheumatology Department of Internal Medicine College of Medicine Seoul National University Seoul National University Bundang Hospital Yun Jong Lee Rheumatoid
More informationRheumatology Updates for the Primary Care Provider
Rheumatology Updates for the Primary Care Provider Jean Tayar, MD, RhMSUS Associate Professor Section of Rheumatology and Clinical Immunology Department of General Internal Medicine UT MD Anderson Cancer
More informationMonoclonal Antibodies in the Management of Rheumatoid Arthritis Prof. John D. Isaacs
John D Isaacs Professor of Clinical Rheumatology Director, Wilson Horne Immunotherapy Centre Newcastle University, UK 1 Rheumatoid arthritis Targeting T-cells Targeting B-cells Costimulation blockade Novel
More informationA Study on Prediction of Rheumatoid Arthritis Using Machine Learning
A Study on Prediction of Rheumatoid Arthritis Using Machine Learning Jihyung Yoo *, Mi Kyoung Lim *, Chunhwa Ihm**, Eun Soo Choi***, Min Soo Kang*** *Dept. of Internal Medicine, Eulji University Hospital,
More informationUnderstanding Arthritis. Training
Understanding Arthritis Training 1 Learning Objectives At the end of this training the learner will: Be able to define Arthritis Describe the symptoms of Arthritis Understand the impact of Arthritis Know
More informationEXAMINING THE CRUCIAL COALITION BETWEEN DERMATOLOGY AND RHEUMATOLOGY IN PSORIATIC ARTHRITIS
EXAMINING THE CRUCIAL COALITION BETWEEN DERMATOLOGY AND RHEUMATOLOGY IN PSORIATIC ARTHRITIS ACTIVITY 1: EARLY COLLABORATION IN THE TREATMENT OF PSA Key Slides COMMON COMORBIDITIES OF PSORIATIC DISEASE
More informationRheumatology E-learning. University of Szeged Department of Rheumatology and Immunology
Rheumatology E-learning University of Szeged Department of Rheumatology and Immunology Rheumatoid arthritis Prevalence: 1:200 the most common chronic polyarthritis worldwide Female:male: 3:1 Peak incidence:
More informationAPPROACH TO PATIENTS WITH POLYARTHRALGIA
APPROACH TO PATIENTS WITH POLYARTHRALGIA Scott Vogelgesang, MD Division of Immunology University of Iowa No conflicts of interest DEFINITIONS Arthralgia joint pain with no evidence of inflammation Arthritis
More informationJuvenile Chronic Arthritis
Juvenile Chronic Arthritis Dr. Christa Visser MBChB MMed (Med Phys) Diploma Musculoskeletal Medicine (UK), Member Society of Orthopaedic Medicine (UK) Childhood Arthritis JCA/JIA/JRA Remember Acute rheumatic
More informationRheumatoid Arthritis 2. Inflammatory Diseases. Definition. Imaging Signs
Rheumatoid Arthritis 2 Definition " Epidemiology Affects 2% of the population Peak incidence (diagnosis) in 4th and 5th decades Women affected 3 4 times more often than men Increased familial incidence
More informationJoint Injuries and Disorders
Joint Injuries and Disorders Introduction A joint is where two or more bones come together. Your joints include the knees, hips, elbows and shoulders. There are many types of joint disorders, including
More informationAutoimmune Diseases. Betsy Kirchner CNP The Cleveland Clinic
Autoimmune Diseases Betsy Kirchner CNP The Cleveland Clinic Disclosures (financial) No relevant disclosures Learning Objectives Explain the pathophysiology of autoimmune disease Discuss safe administration
More informationBiologic agents in Internal Medicine-2018: Targeted therapies for.
Biologic agents in Internal Medicine-2018: Targeted therapies for. Chronic inflammatory diseases affecting the skin Chronic inflammatory diseases affecting the gut Chronic inflammatory diseases affecting
More informationScintigraphic Findings and Serum Matrix Metalloproteinase 3 and Vascular Endothelial Growth Factor Levels in Patients with Polymyalgia Rheumatica
The Open General and Internal Medicine Journal, 29, 3, 53-57 53 Open Access Scintigraphic Findings and Serum Matrix Metalloproteinase 3 and Vascular Endothelial Growth Factor Levels in Patients with Polymyalgia
More informationThe Role of IL-1 and Tumor Necrosis Factor-α in Pathogenesis of Rheumatoid Arthritis
RHEUMATOID THE IRAQI POSTGRADUATE ARTHRITIS MEDICAL JOURNAL The Role of IL-1 and Tumor Necrosis Factor-α in Pathogenesis of Rheumatoid Arthritis Eman Sh.Al-Obeidy*, Shatha F. Abdullah** ABSTRACT: BACKGROUND:
More informationRheumatoid arthritis and Psoriatic arthritis: a guide for Primary Care. Nina Flavin, MD Rheumatology Confluence Health April 13 th, 2018
Rheumatoid arthritis and Psoriatic arthritis: a guide for Primary Care Nina Flavin, MD Rheumatology Confluence Health April 13 th, 2018 No Disclosures Objectives Recognize early signs of RA/PsA what to
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abatacept, for rheumatoid arthritis, 789 Acetaminophen, for low back pain, 735 Acupuncture for fibromyalgia, 753 for low back pain, 738
More informationAnti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis
Q J Med 2007; 100:193 201 doi:10.1093/qjmed/hcm015 Review Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis T.B. NIEWOLD, M.J. HARRISON and S.A. PAGET From the Department
More informationCell-Mediated Immunity and T Lymphocytes
Cell-Mediated Immunity and T Lymphocytes T helper (Th) Cells Peripheral lymhoid tissue thymus Lymphoid stem cell CD8+ CD4+ CD4+ Treg CD8+ CTL + antigen Cytotoxic T lymphocyte CD4+ Th Helper T cell CD4+
More informationPotential Role of Sphingosine 1-Phosphate in the. Pathogenesis of Rheumatoid Arthritis
Potential Role of Sphingosine 1-Phosphate in the Pathogenesis of Rheumatoid Arthritis COMMENTARY for Zhao, C., Fernandes, M.J., Turgeon, M., Tancrede, S., Di Battista, J., Poubelle, P.E. and Bourgoin,
More informationEfficacy of Anakinra in Bone: Comparison to Other Biologics
Advances In Therapy Volume 19 No. 1 January/February 2002 Efficacy of Anakinra in Bone: Comparison to Other Biologics Stephen A. Paget, M.D. Hospital for Special Surgery Department of Rheumatic Disease
More informationStudy of Bone Mineral Density (BMD) in Patients with Rheumatoid Arthritis and its Corelation with Severity of the Disease
26 ORIGINAL ARTICLE Study of Bone Mineral Density (BMD) in Patients with Rheumatoid Arthritis and its Corelation with Severity of the Disease Liyakat Ali Gauri 1, Qadir Fatima 2, Sharanbasu Diggi 3, Asim
More informationRheumatoid Arthritis Update
Rheumatoid Arthritis Update Beth Valashinas, DO, FACOI, FACR Disclosures Speaker for AbbVie Pharmaceuticals Learning Objectives Upon completion of this session, participants should be able to discuss:
More informationArthritis of the Foot and Ankle
Arthritis of the Foot and Ankle Arthritis is inflammation of one or more of your joints. It can cause pain and stiffness in any joint in the body, and is common in the small joints of the foot and ankle.
More informationIntroduction. Rheumatoid Arthritis. Rheumatoid Arthritis. Arthritis vs Rheumatoid Arthritis
Rheumatoid Arthritis Stuart Weisman, MD Boulder Medical Center, P.C. 303-622-3724 Introduction What is rheumatoid arthritis? How is it different than arthritis? What are the symptoms? How is it diagnosed?
More informationUltrasound in Rheumatology
Ultrasound in Rheumatology Alison Hall Consultant MSK Sonographer Research Institute for Primary Care & Health Sciences, Keele University Department of Rheumatology, Cannock Hospital, Royal Wolverhampton
More informationCLOSER LOOK AT SpA. Dr. Mohamed Bedaiwi. Consultant Rheumatologist Rheumatology Unit - KKUH
CLOSER LOOK AT SpA Dr. Mohamed Bedaiwi Consultant Rheumatologist Rheumatology Unit - KKUH Closer look at SpA I. Categories II. SIGN & SYMPTOMS III. X-RAY IV. MRI V. MANAGMENT Spondyloarthritis (SpA)
More informationWhen Aimee Bower s feet started hurting during her recreational
Pain Free at Last Providence rheumatologists provide treatments for the aches of arthritis. Written by DAWN HOFFMAN Photgraphed by MICHAEL NEVEUX When Aimee Bower s feet started hurting during her recreational
More informationA STUDY ON CLINICAL PROFILE OF PATIENTS PRESENTING WITH RHEUMATOID ARTHRITIS IN A TERTIARY CARE HOSPITAL OF PUNE CITY
ORIGINAL ARTICLE A STUDY ON CLINICAL PROFILE OF PATIENTS PRESENTING WITH RHEUMATOID ARTHRITIS IN A TERTIARY CARE HOSPITAL OF PUNE CITY Pradnya M Diggikar 1, Vijayshree S Gokhale 1, Prasanna K Satpathy
More informationAdherence to Non-Infused Biologic Medications Used to Treat Rheumatoid Arthritis (PDC-RA)
Adherence to Non-Infused Biologic Medications Used to Treat Rheumatoid Arthritis (PDC-RA) Description The percentage of patients 18 years and older with rheumatoid arthritis (RA) who met the Proportion
More informationHorizon Scanning Centre November Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330
Horizon Scanning Centre November 2012 Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330 Secukinumab is a high-affinity fully human monoclonal antibody that antagonises
More informationClassification criteria of early rheumatoid arthritis and validation of its performance in a multi-centre cohort
Classification criteria of early rheumatoid arthritis and validation of its performance in a multi-centre cohort J. Zhao 1,2, Y. Su 1, R. Li 1, H. Ye 1, Q. Zou 3, Y. Fang 3, H. Liu 4, X. Li 4, J. Guo 5,
More informationIMMUNE DISORDER. Reference:-Pathophysiology: A 2-in-1 Reference for Nurses. Philadelphia, PA, USA: LWW (PE), 2004.
IMMUNE DISORDER Reference:-Pathophysiology: A 2-in-1 Reference for Nurses. Philadelphia, PA, USA: LWW (PE), 2004. Immune system disorders Hypersensitivity is an exaggerated or inappropriate response that
More informationAbatacept (Orencia) for active rheumatoid arthritis. August 2009
Abatacept (Orencia) for active rheumatoid arthritis August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationCourse instructors (2 hour lecture) 1. Barbara Caffery OD, PhD, FAAO Diplomate, Cornea, Contact Lenses, and Refractive Technologies
Course instructors (2 hour lecture) 1. Barbara Caffery OD, PhD, FAAO Diplomate, Cornea, Contact Lenses, and Refractive Technologies 2. Danielle Robertson, OD, PhD, FAAO, FBCLA Diplomate, Cornea, Contact
More informationRheumatoid arthritis. S Afr Fam Pract REVIEW
South African Family Practice 2014; 56(3):166 171 http://dx.doi.org/10.1080/20786204.2014.932547 Open Access article distributed under the terms of the Creative Commons License [CC BY-NC-ND 4.0] http://creativecommons.org/licenses/by-nc-nd/4.0
More informationPATHOGENESIS OF RHEUMATOID ARTHRITIS
PATHOGENESIS OF RHEUMATOID ARTHRITIS Division of Rheumatology Department of Internal Medicine College of Medicine Seoul National University Seoul National University Bundang Hospital Yun Jong Lee Rheumatoid
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: abatacept_orencia 4/2008 2/2018 2/2019 2/2018 Description of Procedure or Service Abatacept (Orencia ), a
More informationRheumatology Review Update in Internal Medicine COPYRIGHT. Robert H. Shmerling, M.D. Beth Israel Deaconess Medical Center.
Rheumatology Review Update in Internal Medicine Robert H. Shmerling, M.D. Beth Israel Deaconess Medical Center Boston MA Case #1 True statement(s) regarding etanercept and leflunomide, for the treatment
More informationA project study on the analysis of rheumatoid arthritis patients at Dhaka Medical College in Bangladesh
World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original
More informationArthritis Rheumatism Psoriasis
Arthritis Rheumatism Psoriasis 1 / 6 2 / 6 3 / 6 Arthritis Rheumatism Psoriasis You may think that arthritis is a single condition, but there are many forms of arthritis. Each type can be caused by different
More informationThe Genetic Epidemiology of Rheumatoid Arthritis. Lindsey A. Criswell AURA meeting, 2016
The Genetic Epidemiology of Rheumatoid Arthritis Lindsey A. Criswell AURA meeting, 2016 Overview Recent successes in gene identification genome wide association studies (GWAS) clues to etiologic pathways
More informationWhat Contributes to the Progression of Rheumatoid Arthritis?
What Contributes to the Progression of Rheumatoid Arthritis? Article by Abdirahman Hassan PhD, Texila American University E-mail: awale_hassan@hotmail.com Abstract Rheumatoid Arthritis is an autoimmune
More informationExamining the prevalence of rheumatoid arthritis in data from the Clinical Practice Research Datalink
Examining the prevalence of rheumatoid arthritis in data from the Clinical Practice Research Datalink Julian Gardiner, Michael Soljak, Department of Primary Care & Public Health Benjamin Ellis, Arthritis
More informationLack of association of IL-2RA and IL-2RB polymorphisms with rheumatoid arthritis in a Han Chinese population
Lack of association of IL-2RA and IL-2RB polymorphisms with rheumatoid arthritis in a Han Chinese population J. Zhu 1 *, F. He 2 *, D.D. Zhang 2 *, J.Y. Yang 2, J. Cheng 1, R. Wu 1, B. Gong 2, X.Q. Liu
More information